Echo IQ (ASX:EIQ) requested a pre-submission meeting with the US Food and Drug Administration (FDA) to confirm the design of a proposed validation trial of its heart failure screening tool, EchoSolv HF, according to a Tuesday filing with the Australian bourse.
The meeting, expected within 90 days, follows two completed clinical studies that showed that EchoSolv HF's artificial intelligence (AI) technology detected 86% of heart failure cases, compared with a 46% detection rate in standard clinical practice, the filing said.
The company aims to use the meeting to confirm its validation study design with the US FDA and expects regulatory clearance for EchoSolv HF in the second half of 2025.
The AI and medical technology company is in advanced talks with US healthcare organizations to conduct the validation study, set to start next quarter as the final step before FDA submission.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。